NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Fennec Pharmaceuticals Inc. FENC
19 fiscal years on record · USD · FY2025 reported · SEC filings only
$-9.7M
Growth
USD 44.6M
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2025 · Revenue 44.6 · Net income -9.7
Compound annual growth
Revenue compounded at +204.7% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−22 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -14.1% · Net -21.8%
ROE
FY2025 · ROE -65.8%
Each USD of equity lost 66 cents this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · |
| Operating income $B | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| EBITDA $B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | · | · | · | · | · | · | · | · | · | · | −0.0 | −0.0 | −0.0 | · | · | · | · |
| EPS, diluted $ | −0.34 | −0.02 | −0.60 | −0.90 | −0.67 | −0.76 | −0.64 | −0.52 | −0.47 | −0.22 | −0.06 | −0.22 | 0.17 | −0.21 | 0.19 | −0.49 | · | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −65.8 | · | · | −359.2 | −77.4 | −88.5 | −77.0 | −41.1 | −46.5 | −135.5 | −113.5 | · | · | · | · | · | −174.2 | −158.1 | −94.4 |
| Shares out B | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.00 | 0.02 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 69 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 26 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007